The Nb rat prostatic adenocarcinoma's dose response to methotrexate and adriamycin.
The Noble rat prostatic adenocarcinoma, Nb-Pr-A.I.-II, an androgen-insensitive tumor, is the subject of this experiment. Dose responses were carried out with treatment of these tumors with three doses of adriamycin and two doses of methotrexate. Adriamycin treatment resulted in decreased tumor volume and decreased number of metastases in the higher dosage. Methotrexate also decreased metastasis and tumor volume. No animal treated with either of these agents in this protocol had the tumor undergo complete tumor regression, a criteria used in evaluation of chemotherapies with this animal model.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats
D004317:Doxorubicin; D008727:Methotrexate